Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50

Noble Capital Markets analyst Robert LeBoyer maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Outperform and lowers the price target from $60 to $50.